Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease
- PMID: 40905129
- DOI: 10.1161/CIRCINTERVENTIONS.125.015582
Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease
Abstract
Background: Patients with peripheral artery disease experience walking impairment that is incompletely explained by large-artery atherosclerotic occlusive disease and abnormal ankle-brachial index (ABI). Microvascular dysfunction is associated with adverse outcomes, including amputation, but its effect on ambulation is unknown. We tested the hypothesis that skeletal muscle microvascular function directly associates with walking distance, is a more sensitive indicator of walking distance than conduit artery blood inflow, and correlates with ambulatory improvement following peripheral artery disease interventions.
Methods: Sixty-eight participants, including 50 with peripheral artery disease (ABI ≤0.85) and 18 healthy controls, underwent vascular function assessment after sphygmomanometer cuff-induced calf ischemia using magnetic resonance imaging measures of blood oxygenation level-dependent reactivity and arterial spin labeling perfusion reactivity. Functional status was assessed using the 6-minute walk test. A subgroup of patients with peripheral artery disease underwent repeat testing after supervised exercise therapy (n=14) or revascularization (n=14). Multivariable linear regression models were used to assess the association of macrovascular reactive hyperemic blood inflow within the conduit arteries, skeletal muscle microvascular blood oxygenation level-dependent reactivity, and walking distance.
Results: Resting large-artery pressure by ABI (R=0.74; P<0.001), macrovascular blood inflow (R=0.40; P<0.001), and skeletal muscle microvascular blood oxygenation level-dependent reactivity (R=0.66; P<0.001) significantly correlated with the 6-minute walk test distance in univariable vascular testing. In multivariable analysis of each vascular parameter, however, calf skeletal muscle microvascular reactivity was most strongly associated with the 6-minute walk test (β=825.3; P=0.023). In those with repeat testing after intervention, the change in microvascular reactivity, but not ABI or macrovascular blood inflow, significantly correlated with the change in the 6-minute walk test distance (R=0.46; P=0.014).
Conclusions: Microvascular reactivity after ischemia directly associates with walking distance and was a stronger predictor of walking distance than macrovascular blood inflow and ABI. After supervised exercise therapy or revascularization, improvements in microvascular function, but not macrovascular inflow or ABI, correlate with improvement in walking distance. Further study of microvascular dysfunction as a mechanistic driver of ambulatory function is warranted.
Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03490968.
Keywords: blood vessels; capillary resistance; magnetic resonance imaging; microcirculation; peripheral arterial disease; peripheral vascular diseases.
Conflict of interest statement
Dr Aday is on the Clinical Endpoint Committee for Janssen and is consulting for Merck. Dr Donahue is consulting for Pfizer, Inc, Global Blood Therapeutics, Spark Pharmaceuticals, Alterity, Graphite Bio, and Huntington’s Study Group and is on the Advisory Board of Pfizer, Inc, Novartis, and bluebird bio. Dr Beckman is consulting for JanOne, Merck, MingSight, and is on the data safety monitoring committee for Janssen and Novartis. The other authors report no conflicts.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
